StockData
Silexion Therapeutics Corp logo

Silexion Therapeutics Corp (SLXN) shareholders

SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.44−0.21 (-12.73%)

Close on Nov 18, 2026Market cap $868.40KP/E –Yield –

Ownership

Who owns Silexion Therapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 1 sales
Net sold $31.03K

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP)
Joint filing with Avner Lushi (13.80%), Shlomo Noy (13.80%)
1,987,08213.80%13D (active)Aug 15, 2024
Ilan Levin
Joint filing with Moringa Sponsor, LP (17.70%), Moringa Partners Ltd (17.70%)
1,954,05617.70%13D (active) amendmentSep 18, 2026
Moringa Partners Ltd
Joint filing with Ilan Levin (10.60%), Moringa Sponsor, LP (25.00%)
1,391,82710.60%13D (active) amendmentJul 30, 2026
Moringa Sponsor, LP
Joint filing with Moringa Partners Ltd (32.99%), Ilan Levin (32.99%)
1,382,34632.99%13D (active) amendmentMay 14, 2026
CVI Investments, Inc.
Joint filing with Heights Capital Management, Inc. (8.50%)
339,0008.50%13G (passive)Jan 15, 2025
Mitchell P. Kopin
Joint filing with Daniel B. Asher (9.40%), Intracoastal Capital LLC (9.40%)
325,0009.40%13G (passive) amendmentDec 31, 2025
Daniel B. Asher
Joint filing with Mitchell P. Kopin (9.99%), Intracoastal Capital, LLC (9.99%)
244,7719.99%13G (passive)Sep 11, 2025
Easton Jeff
Joint filing with Lind Global Fund III LP (6.40%), Lind Global Partners III LLC (6.40%)
212,5006.40%13G (passive) amendmentSep 30, 2025
Lincoln Alternative Strategies LLC131,2506.18%13G (passive)Sep 12, 2025
Orca Capital AG131,2506.20%13G (passive)Sep 11, 2025
The Goldman Sachs Group, Inc.
Joint filing with Goldman Sachs & Co. LLC (6.60%)
112,2426.60%13G (passive)Dec 31, 2024

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Ilan HadarChairman and CEO, Director16,547Jun 8, 2026
Mitchell ShirvanCSO and CDO8,789Jun 8, 2026
Hadar Mirit HorenshteinCFO and Secretary12,515Jun 8, 2026
Shlomo NoyDirector25,399Feb 25, 2026
Amnon PeledDirector8,237Feb 23, 2026
Ruth AlonDirector10,228Feb 23, 2026
Avner LushiDirector25,399Feb 23, 2026
Dror Yosef AbramovDirector10,180Feb 23, 2026
Ilan LevinDirector, 10% owner–Jan 27, 2026
Moringa Sponsor, LP10% owner458,452Jan 27, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Mitchell Shirvan
CSO and CDO
Jun 4, 2026Award+6,000––8,789
Hadar Mirit Horenshtein
CFO and Secretary
Jun 4, 2026Award+7,500––12,515
Ilan Hadar
Chairman and CEO, Director
Jun 4, 2026Award+10,000––16,547
Mitchell Shirvan
CSO and CDO
Mar 26, 2026Sale−22,818$1.36$31.03K27,889
Shlomo Noy
Director
Feb 20, 2026Award+9,091––25,399
Ruth Alon
Director
Feb 20, 2026Award+9,091––10,228
Hadar Mirit Horenshtein
CFO and Secretary
Feb 20, 2026Award+49,726––50,146
Avner Lushi
Director
Feb 20, 2026Award+9,091––25,399
Dror Yosef Abramov
Director
Feb 20, 2026Award+9,091––10,180
Ilan Hadar
Chairman and CEO, Director
Feb 20, 2026Award+64,350––65,471
Amnon Peled
Director
Feb 20, 2026Award+7,576––8,237
Mitchell Shirvan
CSO and CDO
Feb 20, 2026Award+49,726––50,707
Moringa Sponsor, LP
10% owner
Sep 15, 2025Award+450,000$4.00$1.80M456,970
Moringa Sponsor, LP
10% owner
Aug 7, 2025Other−5,550––6,970
Dror Yosef Abramov
Director
Feb 9, 2025Award+794––794
Avner Lushi
Director
Feb 9, 2025Award+1,587––1,587
Amnon Peled
Director
Feb 9, 2025Award+661––661
Ruth Alon
Director
Feb 9, 2025Award+794––794
Shlomo Noy
Director
Feb 9, 2025Award+1,587––1,587

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 1M shares a day
Change since last report
-49.5%
From 0M shares
Short volume, 20 days
45.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Silexion Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,853,952 shares on Sep 30, 2026 over the last 90 days.

See a number that looks wrong?